留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展

卜晓琳 毕新岭 徐晓光 高志祥 李慧 顾军

卜晓琳, 毕新岭, 徐晓光, 高志祥, 李慧, 顾军. 甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展[J]. 药学实践与服务, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
引用本文: 卜晓琳, 毕新岭, 徐晓光, 高志祥, 李慧, 顾军. 甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展[J]. 药学实践与服务, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
BU Xiaolin, BI Xinling, XU Xiaoguang, GAO Zhixiang, LI Hui, GU Jun. The research progress of parathyroid hormone and parathyroid hormone-related peptide in skin disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
Citation: BU Xiaolin, BI Xinling, XU Xiaoguang, GAO Zhixiang, LI Hui, GU Jun. The research progress of parathyroid hormone and parathyroid hormone-related peptide in skin disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002

甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展

doi: 10.3969/j.issn.1006-0111.2014.06.002
基金项目: 浦东新区卫生系统优秀青年医学人才培养计划(PWRq2013-02).

The research progress of parathyroid hormone and parathyroid hormone-related peptide in skin disease

  • 摘要: 甲状旁腺素(PTH)和甲状旁腺素相关肽(PTHrP)是一类多肽类激素,它们具有相似的基因结构、相同的膜受体,在人体钙、磷代谢过程中起着重要的调节作用。PTH和PTHrP及其受体除表达于肿瘤组织外,在皮肤、毛囊等正常组织也有表达。它们对表皮增殖分化、毛发生长的生理作用等方面,有望成为银屑病等常见皮肤病的治疗新靶点。
  • [1] Oquendo M, Abramovits W, Morrell P.Topical vitamin D analogs available to treat psoriasis[J]. Skin Med, 2012,10(6):356-360.
    [2] Shah KN.Diagnosis and treatment of pediatric psoriasis: current and future[J]. Am J Clin Dermatol,2013,14(3):195-213.
    [3] Holick MF. Clinical efficacy of 1,25-dihydroxyvitamin D3 and its analogues in the treatment of psoriasis[J]. Retinoids,1998,14: 12-17.
    [4] Cupp ME, Nayak SK, Adem AS, et al.Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways[J]. J Pharmacol Exp Ther,2013,345(3):404-418.
    [5] Whitfield JF, Isaacs RJ, Chakravarthy B, et al.Stimulation of protein kinase C activity in cells expressing human parathyroid hormone receptors by C-and N-terminally truncated fragments of parathyroid hormone 1-34[J]. J Bone Miner Res, 2001,16(3):441-447.
    [6] Strewler GJ,Nissenson RA.Hypercalcemia in malignancy[J]. West J Med,1990,153(6):635-640.
    [7] Wysolmerski JJ, Broadus AE.Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein[J]. Annu Rev Med, 1994,45:189-200.
    [8] Strewler GJ. The parathyroid hormone-related protein[J]. Endocrinol Metab Clin North Am, 2000,29(3):629-645.
    [9] Milanesi A, Yu R, Wolin EM.Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors: report of six cases[J]. Pancreatology, 2013,13(3):324-326.
    [10] Nilubol N, Weisbrod AB, Weinstein LS,et al.Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy[J]. World J Surg,2013,37(8):1966-1972.
    [11] Hiremath M, Wysolmerski J.Parathyroid hormone-related protein apecifies the mammary mesenchyme and regulates embryonic mammary sevelopment[J]. J Mamm Gland Biol Neopl,2013,18(2):171-177.
    [12] Jia T, Qureshi AR, Brandenburg V,et al.Determinants of dibroblast growth dactor-23 and parathyroid hormone variability in dialysis patients[J]. Am J Nephrol, 2013,37(5):462-471.
    [13] Metzger M, Houillier P, Gauci C, et al.Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold[J].J Clin Endocrinol Metab,2013,98(7):2922-2928.
    [14] Urea P.The PTH/PTHrP receptor: biological implications[J].Nefrologia,2003,23(Suppl 2):12-17.
    [15] Errazahi A, Bouizar Z, Lieberherr M,et al.Functional type I PTH/PTHrP receptor in freshly isolated newborn rat keratinocytes: identification by RT-PCR and immunohistochemistry[J].J Bone Miner Res, 2003,18(4):737-750.
    [16] Calvi LM, Adams GB, Weibrecht KW,et al. Osteoblastic cells regulate the haematopoietic stem cell niche[J].Nature, 2003,425(6960):841-846.
    [17] Weber JM, Adams GB, Guaman ML, et al. Parathyroid treatment improves survival after bone marrow transplantation and increases osteoblastic expression of the Notch ligand Jagged 1[J].J Bone Miner Res,2004,19:S407.
    [18] Aho S.Soluble form of Jagged1: unique product of epithelial keratinocytes and a regulator of keratinocyte differentiation[J].J Cell Biochem, 2004,92(6):1271-1281.
    [19] Holick MF, Nussbaum S, Persons KS. PTH-like humoral hypercalcemia factor (HHF) of malignancy may be an epidermal differentiation factor:synthetic hHHF(1-34) NH2 inhibits proliferation and induces terminal differentiation of cultured human kerationcytes[J].J Bone Miner Res,1988,3:S214.
    [20] Hanafin NM, Chen TC, Heinrich G,et al.Cultured human fibroblasts and not cultured human keratinocytes express a PTH/PTHrP receptor mRNA[J].J Invest Dermatol,1995,105(1):133-137.
    [21] Whitfield JF.Taming psoriatic keratinocytes-PTHs'uses go up another notch[J].J Cell Biochem,2004,93(2):251-256.
    [22] KaiserSM, Sebag M, Rhim JS,et al.Antisense-mediated inhibition of parathyroid hormone-related peptide production in a keratinocyte cell line impedes differentiation[J].Mol Endocrinol,1994,8(2):139-147.
    [23] Juhlin L, Hagforsen E, Juhlin C.Parathyroid hormone related protein is localized in the granular layer of normal skin and in the dermal infiltrates of mycosis fungoides but is absent in psoriatic lesions[J].Acta Derm Venereol,1992,72(2):81-83.
    [24] Whitfield JF, Chakravarthy BR, Durkin JP,et al.Parathyroid hormone stimulates protein kinase C but not adenylate cyclase in mouse epidermal keratinocytes[J].J Cell Physiol, 1992,150(2):299-303.
    [25] Dore RK.Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis[J].Patient Prefer Adher, 2013,7:435-446.
    [26] Horwitz MJ, Augustine M, Kahn L,et al.A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study[J].J Bone Miner Res, 2013,28(11):2266-2276.
    [27] Holick MF, Chimeh FN, Ray S.Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial[J].Br J Dermatol, 2003,149(2):370-376.
    [28] Peters EM, Foitzik K, Paus R,et al.A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist[J].J Invest Dermatol, 2001,117(2):173-178.
  • [1] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [2] 何亚伦, 祁智, 常杰.  消胀通便膏在晚期肝癌患者阿片类药物相关性便秘的应用研究 . 药学实践与服务, 2024, 42(12): 1-4. doi: 10.12206/j.issn.2097-2024.202309009
    [3] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [4] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [5] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
    [6] 徐璐璐, 刘爱军.  丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
    [7] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
    [8] 张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳.  基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
    [9] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [10] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
  • 加载中
计量
  • 文章访问数:  3998
  • HTML全文浏览量:  313
  • PDF下载量:  115
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-06-13
  • 修回日期:  2013-12-02

甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展

doi: 10.3969/j.issn.1006-0111.2014.06.002
    基金项目:  浦东新区卫生系统优秀青年医学人才培养计划(PWRq2013-02).

摘要: 甲状旁腺素(PTH)和甲状旁腺素相关肽(PTHrP)是一类多肽类激素,它们具有相似的基因结构、相同的膜受体,在人体钙、磷代谢过程中起着重要的调节作用。PTH和PTHrP及其受体除表达于肿瘤组织外,在皮肤、毛囊等正常组织也有表达。它们对表皮增殖分化、毛发生长的生理作用等方面,有望成为银屑病等常见皮肤病的治疗新靶点。

English Abstract

卜晓琳, 毕新岭, 徐晓光, 高志祥, 李慧, 顾军. 甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展[J]. 药学实践与服务, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
引用本文: 卜晓琳, 毕新岭, 徐晓光, 高志祥, 李慧, 顾军. 甲状旁腺素和甲状旁腺素相关肽在皮肤病中的研究进展[J]. 药学实践与服务, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
BU Xiaolin, BI Xinling, XU Xiaoguang, GAO Zhixiang, LI Hui, GU Jun. The research progress of parathyroid hormone and parathyroid hormone-related peptide in skin disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
Citation: BU Xiaolin, BI Xinling, XU Xiaoguang, GAO Zhixiang, LI Hui, GU Jun. The research progress of parathyroid hormone and parathyroid hormone-related peptide in skin disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 405-408. doi: 10.3969/j.issn.1006-0111.2014.06.002
参考文献 (28)

目录

    /

    返回文章
    返回